StonvexLoading…
StonvexStonvexStonvexCore line items from BTMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $192.22M | $197.19M | $185.36M | $164.96M |
Operating Income | $35.55M | $31.61M | $28.66M | $-60.72M |
Net Income | $27.05M | $3.16M | $3.32M | $-969.00K |
EPS (Diluted) | $0.74 | $0.09 | $0.13 | $-0.12 |
Total Assets | $107.61M | $122.37M | $155.29M | $111.64M |
Total Liabilities | $158.01M | $224.57M | $191.84M | $169.92M |
Cash & Equivalents | $24.12M | $39.34M | $89.00M | $79.23M |
Free Cash Flow OCF − CapEx | $30.18M | $38.81M | $26.52M | $-9.49M |
Shares Outstanding | 36.67M | 34.27M | 25.71M | 58.22M |